MINNEAPOLIS, July 15, 2019 (GLOBE NEWSWIRE) -- FemPulse Corporation (FemPulse), a private, clinical-stage bioelectronic medicine company developing a novel therapy for the personalized treatment of overactive bladder (OAB) in women, announced today that the first participant has been enrolled in the Company’s clinical trial evaluating physiological responses to therapy delivered with the FemPulse System.  Observations from this feasibility study can further help elucidate the mechanisms of action and facilitate tailoring treatment plans for individual patients.

Dr. Adam Loavenbruck, a neurologist at Hennepin Healthcare in Minneapolis and the Principal Investigator of the study, commented, “The FemPulse System is a promising advancement in the OAB field as it represents a potential solution that could offer women the ability to improve their quality of life and regain their independence. This study will help further establish the ability to individualize therapy parameters and I look forward to working with more patients.”

Dr. Alexandra Haessler, Chief Medical Officer and Founder of FemPulse, added, “Currently, there are limited convenient and effective treatment options for women suffering with OAB. The enrollment of our first participant in this study is an important milestone as we strive to provide a minimally invasive treatment that will improve the quality of life for women impacted by this condition. We look forward to the final results as a further validation of our mission to address this unmet need with a truly unique solution.”

The clinical trial is an open-label, single group assignment, to investigate the FemPulse system for the treatment of OAB in women. Participants will wear a FemPulse device and will be monitored non-invasively during activation of the device for up to six hours. The company anticipates data readout in the second half of 2019.

More information about the trial is available at www.clinicaltrials.gov, identifier (NCT number): NCT04001426.

About FemPulse Corporation
FemPulse Corporation is a privately held clinical-stage bioelectronic medicine company focused on treating women with overactive bladder. The company is developing the FemPulse System, an elegant neuromodulation platform, intended to provide mild electrical nerve stimulation to regulate bladder function and relieve the symptoms of OAB. The small, vaginal ring is disposable and may remain indwelling for days or weeks, affording discreet, personalized, continuous and self-managed therapy. For more information, visit www.fempulse.com.

Investor Contact:
Emma Poalillo
The Ruth Group
646-536-7024
epoalillo@theruthgroup.com

Media Contact:
Kirsten Thomas
The Ruth Group
508-280-6592
kthomas@theruthgroup.com